Analysis of Aqueous and Vitreous Humor (ARK)
Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole
About this trial
This is an interventional basic science trial for Proliferative Diabetic Retinopathy focused on measuring Tractional retinal detachment, Exudative retinal detachment, Macular hole, Neovascular glaucoma
Eligibility Criteria
Inclusion Criteria:
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age > 18 years
- Subjects with a diagnosis of tractional retinal detachment secondary to proliferative diabetic retinopathy, age-related macular degeneration with tractional or exudative retinal detachment, macular hole, epiretinal membrane, or neovascular glaucoma.
Exclusion Criteria:
- Subjects with history of vitrectomy in the study eye
- Presence of vitreous hemorrhage
- Subjects with history of laser photocoagulation in the study eye within 3 months of vitrectomy
- Subjects unwilling to undergo pars plana vitrectomy
- Subjects unwilling to receive intravitreal ranibizumab prior to pars plana vitrectomy unless diagnosis of macular hole or epiretinal membrane
- Subjects who may need or have received systemic anti-VEGF for oncology in the past year
- Subjects with history of anti-VEGF injection within 4 months before vitrectomy
Sites / Locations
- California Retina Consultants - Santa Barbara OfficeRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Ranibizumab
Control
Subjects undergoing surgery for neovascular glaucoma, diabetic retinopathy, or tractional Retinal Detachment due to AMD will receive one intravitreal injection of ranibizumab within 2 weeks of their surgery. Vitreous and aqueous humor samples will be collected during the surgery. Serum samples may be collected before, during, or after surgery.
Subjects undergoing surgery for ERM or macular hole will NOT receive an injection of ranibizumab, but will have vitreous, and aqueous humor samples collected during surgery (no serum collection).